The newest generation of GLP-1 drugs are being hailed by some as “miracle drugs” for the treatment of obesity. But GLP-1s are expensive, insurance coverage is limited, and not everyone with obesity can and or wants to take them. In this episode, which is based on Goldman Sachs Research’s latest Top of Mind report, obesity medicine physician Dr. Fatima Cody Stanford and Jonathan Gruber, professor of economics and chairman of the Economics Department at MIT, discuss how large the addressable market for GLP-1s actually is and the implications for US fiscal health.
If you want more insights from Goldman Sachs, make sure to visit GS.com and sign up for Briefings, a weekly newsletter from Goldman Sachs about trends spanning markets, industries, and the global economy.
Is 2022 the Endemic Year?
As Rates Reprice and Stocks Sell Off, What’s Next?
Goldman Sachs’ David Solomon on the Firm’s Performance, the Global Economy and What to Expect in 2022
Understanding the Metaverse and Web 3.0
What’s Next for M&A
Accelerating Transition: Market Tools for ESG
Investing in Climate Change 2.0
Redefining the Retirement Landscape
Accelerating Transition: Public-Private Partnerships
What India’s Digital Transformation Means for Markets, Investors and Economic Growth
Accelerating Transition: Nature Based Solutions
What’s Ahead for Global Economies and Markets in 2022?
Accelerating Transition: Carbonomics
Inflation: Here Today, Gone Tomorrow?
Accelerating Transition
An Evolution in the Cybersecurity Landscape
Why Investors Are Shopping for Consumer Retail
Europe at a Crossroads
The Small Business Perspective: How Owners Are Dealing With Worker Shortages, Inflation and Supply Chain Delays
The Impact of Rising Natural Gas Prices
Create your
podcast in
minutes
It is Free
The Commercial Edge: Unleash the Power of People
The emPOWERed Half Hour
TED Radio Hour
FT Alphachat
Freakonomics Radio
Stephanomics
Odd Lots